NCT04998786

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Nantes University Hospital · Academic / Other
• Sex: All
• Age: 70 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple myeloma at first relapse . The patient population will consist of adult men and women more than 70 years, who meet eligibility criteria. Following the screening period, patients will be enrolled and treated then, they will receive therapy with Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression.

Conditions

• Multiple Myeloma at First Relapse

Interventions

Type	Name	Description
DRUG	Ixazomib	Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress
DRUG	Iberdomide	Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress
DRUG	Dexamethasone Oral	Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22

Timeline

• Start date: 2021-12-14
• Primary completion: 2030-01-01
• Completion: 2030-01-01
• First posted: 2021-08-10
• Last updated: 2025-04-06

Locations

21 sites across 1 country: France